Grunenthal Obtains German Approval For New Quinolone AntiBiotic [Gatifloxacin]
November 8, 2001
Kyorin Pharmaceutical Co., Ltd. (President: Ikuo Ogihara, Head Office: Tokyo) announced that Grunenthal (Head Office: Aachen, Germany) has obtained approval from the German Federal Institute for Drugs and Medical Devices for Kyorin's new quinolone antibiotic, Gatifloxacin, on October 22, 2001.
Gatifloxacin was licensed to Grnenthal from Kyorin Pharmaceutical Company, Ltd. in 1995 for development, production and marketing in Europe, the Middle East and certain parts of South America. Grunenthal filed the application in Germany as Reference Member State in December 1999 in accordance with the European Union's mutual recognition approval systems for medicinal products. Following official German approval application will then be submitted for other European countries.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.